EVALUATION OF PHARMACOECONOMIC DIRECT COST IN DIABETES PATIENTS

  • Venkateswarlu Konuru Head of the Departmentand Assistant Professor. Department of Clinical Pharmacy, St. Peter’s Institute of Pharmaceutical sciences, Vidyanagar, Hanamkonda, Kakatiya University Warangal-506001 Telangana, India
  • Kamala Sangam Department of Clinical Pharmacy, St. Peter’s Institute of Pharmaceutical sciences, Vidyanagar, Hanamkonda, Kakatiya University Warangal-506001 Telangana, India
  • Anifa Mohammed Department of Clinical Pharmacy, St. Peter’s Institute of Pharmaceutical sciences, Vidyanagar, Hanamkonda, Kakatiya University Warangal-506001 Telangana, India
  • Swathi Kanneganti Department of Clinical Pharmacy, St. Peter’s Institute of Pharmaceutical sciences, Vidyanagar, Hanamkonda, Kakatiya University Warangal-506001 Telangana, India

Abstract

Objective:  Diabetes Mellitus (DM) is a major cause of disability, morbidity and mortality Worldwide. The objective of this study is to evaluate the Pharmacoeconomic direct health care cost in type II Diabetes with complications and Diabetes alone: A cost of illness study.

Methods:  A Prospective observational study was conducted for one year at the Care diabetes Center; Warangal. The enrolled patients were followed and the information collected contains: total direct costs, which include direct medical costs and direct nonmedical cost. The data observed was analyzed for the average cost incurred in treating the diabetic patient.

Results:  The total average costs per diabetic patient without complications was Rs. 8695.7±1341,  this includes the average direct medical cost Rs. 6366.50± 561.12, the average lab cost Rs. 1368.84±64.8, the average direct non Medical Cost was Rs. 960.36±14.04 compared to  those with DM complications,the total average cost was Rs. 12960.73±549.96 for macro vascular complications, Rs. 11039.11±265.36 for micro vascular complications. To treat Diabetes with comorbidities which include both micro and macro complications the total average cost was  Rs. 16658.13±1393.44, the average direct medical cost was Rs. 14071.77±2884.68, the average lab cost Rs. 1628.04±51, the average direct non Medical Cost was Rs.958.32±13.08. The costs were found to increase progressively with the increase in the number of complications. Costs also differed significantly across the types of complications.

Conclusion: Our study concludes that the cost of Diabetes with complications resulted about 2 times higher than compared to Diabetes alone.

Key words:  Cost analysis; diabetes; economics; health care; direct medical cost; non medical cost

Author Biography

Venkateswarlu Konuru, Head of the Departmentand Assistant Professor. Department of Clinical Pharmacy, St. Peter’s Institute of Pharmaceutical sciences, Vidyanagar, Hanamkonda, Kakatiya University Warangal-506001 Telangana, India
Department of Pharmacy Practice

References

1. Shargel L, Mutnick AH, Souney PF, Swanson LN. Comprehensive Pharmacy Review. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009. p. 850-70, 1165-93.
2. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2008. p. 116-35, 217-36.
3. Wild S, Roglic G, Green A, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.
4. Siegel K, Narayan KM, Kinra S. Finding a policy solution to India’s diabetes epidemic. Health Aff (Millwood) 2008;27(4):1077-90.
5. Kapur A. Influence of socio-economic factors on diabetes care. Int J Diabetes Dev Ctries 2001;21:77.
6. Iram M, Rani S, Hiremath R. Pharmacoeconomics need for the day. Indian J Pharm Pract 2009;2(3):16-8.
7. Briggs AH, Levy AR. Pharmacoeconomics and pharmacoepidemiology: Curious bedfellows or a match made in heaven? Pharmacoeconomics 2006;24(11):1079-86.
8. Bootman JL, Raymond JT, McGhan WF. Introduction to Pharmacoeconomics. Ohio: Harvey Whitney Books; 1996. p. 7-9.
9. Zhang P, Engelgau MM, Norris SL, Gregg EW, Narayan KM. Application of economic analysis to diabetes and diabetes care. Ann Intern Med 2004;140(11):972-7.
10. Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res 2007;7:189.
11. Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, et al. The economic costs of diabetes: A population-based study in Tehran, Iran. Diabetologia 2009;52(8):1520-7.
12. Rekik M, Abid M, Hachicha J, Abbes R, Moujahed M, Jarraya A. Direct cost of the ambulatory management of diabetes at the outpatient clinic of the National Social Security Fund of Sfax (Tunisia). Bull World Health Organ 1994;72(4):611-4.
13. Elrayah-Eliadarous H, Yassin K, Eltom M, Abdelrahman S, Wahlström R, Ostenson CG. Direct costs for care and glycaemic control in patients with Type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes 2010;118(4):220-5.
14. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003;81(1):19-27.
15. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26(3):917-32.
16. Akari S, Mateti UV, Kunduru BR. Health-care cost of diabetes in South India: A cost of illness study. J Res Pharm Pract 2013;2(3):114-7.
Statistics
570 Views | 373 Downloads
Citatons
How to Cite
Konuru, V., K. Sangam, A. Mohammed, and S. Kanneganti. “EVALUATION OF PHARMACOECONOMIC DIRECT COST IN DIABETES PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 4, Apr. 2017, pp. 38-40, doi:10.22159/ajpcr.2017.v10i4.8510.
Section
Original Article(s)